IQVIA Holdings Inc. (IQV)
USD 190.97
(-2.88%)
USD 190.97
(-2.88%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.05 Billion USD | -35.86% |
| 2022 | 3.2 Billion USD | -0.84% |
| 2021 | 3.22 Billion USD | 4.94% |
| 2020 | 3.07 Billion USD | 4.77% |
| 2019 | 2.93 Billion USD | 2.77% |
| 2018 | 2.85 Billion USD | 9.21% |
| 2017 | 2.61 Billion USD | 101.23% |
| 2016 | 1.3 Billion USD | 41.15% |
| 2015 | 920.98 Million USD | 4.38% |
| 2014 | 882.33 Million USD | 2.54% |
| 2013 | 860.51 Million USD | 5.23% |
| 2012 | 817.75 Million USD | 7.27% |
| 2011 | 762.29 Million USD | 9.15% |
| 2010 | 698.4 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 508 Million USD | -8.63% |
| 2024 Q2 | 509 Million USD | 0.2% |
| 2024 Q3 | 800 Million USD | 62.67% |
| 2023 Q4 | 556 Million USD | -30.41% |
| 2023 Q3 | 799 Million USD | 7.83% |
| 2023 FY | 2.05 Billion USD | -35.86% |
| 2023 Q1 | 766 Million USD | -18.51% |
| 2023 Q2 | 741 Million USD | -3.26% |
| 2022 Q4 | 940 Million USD | 22.88% |
| 2022 Q3 | 765 Million USD | 1.59% |
| 2022 Q2 | 753 Million USD | 1.35% |
| 2022 FY | 3.2 Billion USD | -0.84% |
| 2022 Q1 | 743 Million USD | -7.59% |
| 2021 Q1 | 765 Million USD | -8.38% |
| 2021 Q2 | 825 Million USD | 7.84% |
| 2021 Q3 | 834 Million USD | 1.09% |
| 2021 Q4 | 804 Million USD | -3.6% |
| 2021 FY | 3.22 Billion USD | 4.94% |
| 2020 Q4 | 835 Million USD | 7.19% |
| 2020 Q3 | 779 Million USD | 5.41% |
| 2020 Q2 | 739 Million USD | 2.21% |
| 2020 Q1 | 723 Million USD | -9.4% |
| 2020 FY | 3.07 Billion USD | 4.77% |
| 2019 Q2 | 730 Million USD | 2.24% |
| 2019 FY | 2.93 Billion USD | 2.77% |
| 2019 Q4 | 798 Million USD | 14.99% |
| 2019 Q3 | 694 Million USD | -4.93% |
| 2019 Q1 | 714 Million USD | -3.12% |
| 2018 Q4 | 737 Million USD | 3.51% |
| 2018 Q2 | 706 Million USD | 0.57% |
| 2018 FY | 2.85 Billion USD | 9.21% |
| 2018 Q1 | 702 Million USD | -5.39% |
| 2018 Q3 | 712 Million USD | 0.85% |
| 2017 Q2 | 615 Million USD | 0.49% |
| 2017 Q4 | 742 Million USD | 14.68% |
| 2017 Q1 | 612 Million USD | 5.52% |
| 2017 Q3 | 647 Million USD | 5.2% |
| 2017 FY | 2.61 Billion USD | 101.23% |
| 2016 FY | 1.3 Billion USD | 41.15% |
| 2016 Q3 | 233.64 Million USD | -6.75% |
| 2016 Q2 | 250.56 Million USD | 11.11% |
| 2016 Q1 | 225.51 Million USD | -7.6% |
| 2016 Q4 | 580 Million USD | 148.24% |
| 2015 Q1 | 219.6 Million USD | -2.42% |
| 2015 Q4 | 244.06 Million USD | 5.47% |
| 2015 Q3 | 231.41 Million USD | 2.44% |
| 2015 Q2 | 225.89 Million USD | 2.87% |
| 2015 FY | 920.98 Million USD | 4.38% |
| 2014 Q3 | 219.02 Million USD | 0.01% |
| 2014 Q2 | 219.01 Million USD | -0.1% |
| 2014 Q1 | 219.24 Million USD | -5.82% |
| 2014 FY | 882.33 Million USD | 2.54% |
| 2014 Q4 | 225.05 Million USD | 2.75% |
| 2013 Q4 | 232.79 Million USD | 16.65% |
| 2013 Q1 | 199.3 Million USD | -7.57% |
| 2013 FY | 860.51 Million USD | 5.23% |
| 2013 Q2 | 228.83 Million USD | 14.82% |
| 2013 Q3 | 199.57 Million USD | -12.79% |
| 2012 FY | 817.75 Million USD | 7.27% |
| 2012 Q1 | 205.79 Million USD | 0.0% |
| 2012 Q4 | 215.63 Million USD | 11.86% |
| 2012 Q2 | 203.54 Million USD | -1.09% |
| 2012 Q3 | 192.78 Million USD | -5.29% |
| 2011 FY | 762.29 Million USD | 9.15% |
| 2010 FY | 698.4 Million USD | 0.0% |
| 2001 Q3 | 517 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agilent Technologies, Inc. | 2.11 Billion USD | 2.931% |
| Charles River Laboratories International, Inc. | 885.29 Million USD | -131.9% |
| Quest Diagnostics Incorporated | 1.61 Billion USD | -27.516% |
| Danaher Corporation | 8.83 Billion USD | 76.755% |
| Enzo Biochem, Inc. | 26.99 Million USD | -7504.549% |
| Laboratory Corporation of America Holdings | 2.02 Billion USD | -1.563% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -88.454% |
| Qiagen N.V. | 777.67 Million USD | -163.991% |
| Revvity, Inc. | 874.01 Million USD | -134.893% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 79.979% |
| Waters Corporation | 943.51 Million USD | -117.59% |